Top Markets
#1 EXOD EXOD +56.80%
#2 CoW Protocol CoW Protocol +54.01%
#3 Glidr Glidr +41.01%
#4 Cysic Cysic +38.33%
#5 Walrus Walrus +27.54%
#6 Humanity Humanity +25.25%
#7 Enso Enso +17.24%
#8 Tutorial Tutorial +15.94%
#9 The Black Bull The Black Bull +14.95%
#10 Codatta Codatta +14.84%
Coin of the day
EXOD EXOD
Settings
Language
ENGLISH
Currency
USD
Theme
DermTech, Inc. DermTech, Inc.

DermTech, Inc.

DMTK
Rank in Stocks #37065
DermTech, Inc., a molecular diagnostics firm headquartered in La Jolla,... DermTech, Inc., a molecular diagnostics firm headquartered in La Jolla, California, specializes in creating and bringing to market advanced, non-invasive genomic tests. Operating within the United States, their innovative solutions facilitate the diagnosis of various dermatological issues, including skin cancer, inflammatory conditions, and age-related skin concerns. A cornerstone of their offerings is the DermTech Melanoma Test (DMT), a sophisticated gene expression analysis. This assay plays a crucial role in enhancing the early identification of genomic abnormalities, effectively aiding in the exclusion of melanoma and often removing the need for invasive surgical biopsies of suspicious pigmented lesions. The company further provides specialized adhesive kits for convenient skin sample collection. Additionally, they offer gene expression assays designed to analyze key inflammatory pathways such, as Th1, Th2, IFN-gamma, and Th17. Looking ahead, DermTech is actively developing a pipeline of new products, which includes DNA risk assessment tools for UV damage, diagnostic tests for non-melanoma skin cancers, and rule-out tests for cutaneous T-cell lymphoma. They also extend their services by delivering health-related information and support through digital and telecommunication platforms. DermTech's diagnostic products and services are primarily targeted towards medical professionals in the fields of pathology and oncology.
Share Price
$0.069
Last synced: 2024-07-22
Market Cap
$2.06M
Change (1 day)
-1.43%
Change (1 year)
0.00%
Country
US
Trade DermTech, Inc. (DMTK)

Category

Healthcare
Revenue for DermTech, Inc. (DMTK)
Revenue in Mar 2024 TTM: $15.66M
According to DermTech, Inc. latest financial reports the company's current revenue (TTM) is $15.66M. In 2022 the company made a revenue of $14.52M an increase over the revenue in the year 2021 that was $11.84M. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for DermTech, Inc. from 2012 to 2026
Revenue at the end of each year
Year Revenue Change
2026 (TTM) $15.66M 2.41%
2023 $15.30M 5.36%
2022 $14.52M 22.64%
2021 $11.84M 101.16%
2020 $5.89M 74.94%
2019 $3.36M 0.00%
2018 0.00 0.00%
2017 0.00 0.00%
2013 0.00 0.00%
2012 0.00 0.00%
Revenue for similar companies or competitors
Company Revenue Revenue Difference Country
Thermo Fisher Scientific Inc. Thermo Fisher Scientific Inc.
Thermo Fisher Scientific Inc.
TMO.US
 $46.34B 295,712.05%
US
Danaher Corporation Danaher Corporation
Danaher Corporation
DHR.US
 $25.11B 160,184.73%
US
WuXi AppTec Co., Ltd. WuXi AppTec Co., Ltd.
WuXi AppTec Co., Ltd.
603259.SS
 - -
CN
Natera, Inc. Natera, Inc.
Natera, Inc.
NTRA.US
 $2.71B 17,182.16%
US
IDEXX Laboratories, Inc. IDEXX Laboratories, Inc.
IDEXX Laboratories, Inc.
IDXX.US
 $4.55B 28,968.07%
US